GlobeNewswire

Nanobiotix to Participate in Investor Conferences in November
09/11/2026
PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
NANOBIOTIX PARTICIPERA À PLUSIEURS CONFÉRENCES INVESTISSEURS EN NOVEMBRE
09/11/2026
PARIS et CAMBRIDGE, Mass., 09 nov. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Surgery Partners, Inc. Announces Third Quarter 2026 Results
09/11/2026
BRENTWOOD, Tenn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the [...]
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
09/11/2026
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – – Deprioritize development of tagmokitug/toripalimab in other [...]
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
09/11/2026
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 [...]
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
09/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct [...]
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
09/11/2026
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection Phase 3 C-FORWARD Trial for HCV on Track for [...]
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
09/11/2026
2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 mi llion (previously [...]
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
09/11/2026
14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategy GAAP gross margin improved by over 170 bps vs. prior year to 45.2% Received initial orders of Colli-Pee®•Dx and [...]
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
09/11/2026
~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill ® platform technology ~ ~ Enrollment continues in RT-114 Phase 1a expansion cohort; [...]
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
09/11/2026
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of [...]
Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
09/11/2026
Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year- [...]
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
09/11/2026
First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation [...]
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
09/11/2026
DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC DENALI Part 2c enrollment [...]
MapLight Therapeutics to Participate in Upcoming Investor Conference
09/11/2026
SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference: Event : [...]
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
09/11/2026
Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the [...]
Stryker announces intention to nominate Jim Davis to board of directors
09/11/2026
Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the [...]
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
09/11/2026
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a new partnership with Pet Supermarket to offer pet prescription [...]
Apollomics Reports First-Half 2026 Financial Results
09/11/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026 ( [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum